ARID2
ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.
Overview
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, somatic mutation 0.98). IntOGen calls it a driver in 36 cohorts (3 activating, 33 loss-of-function), covering Cholangiocarcinoma, Cutaneous Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Glioblastoma, Gallbladder Cancer and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.
- 1 · What it is
ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.
- 2 · What goes wrong in cancer
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF).
- 3 · How drugs use it
No product in this corpus aims at ARID2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:18037 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q68CP9 (protein name, function text, keywords and locations (REST API)); CIViC gene ARID2 (1 evidence items, 0 assertions, 2 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000189079 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.53, oesophageal cancer 0.57, hepatocellular carcinoma 0.63, melanoma 0.72, skin cancer 0.67, lung cancer 0.51 (GraphQL API, CC0)); IntOGen ARID2 (driver in 36 cohorts (Act 3, LoF 33); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes. May be involved in regulating transcriptional activation of cardiac genes. Location: Nucleus (UniProt). Locus 12q12 (HGNC).
- Skin cancer: Open Targets association 0.67 with skin cancer (MONDO_0002898)
- Hepatocellular carcinoma: Open Targets association 0.63 with hepatocellular carcinoma (MONDO_0007256); CIViC evidence names this disease
- Oesophageal cancer: Open Targets association 0.57 with oesophageal cancer (MONDO_0007576); IntOGen driver in 3 cohorts (ESCA, ESCC)
- Gastric & gastro-oesophageal junction cancer: IntOGen driver in 2 cohorts (STAD)
- Biliary tract cancer: Open Targets association 0.57 with biliary tract cancer (MONDO_0003060)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 33 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"ARID2" OR ABSTRACT:"ARID2" OR TITLE:"AT-rich interaction domain 2" OR ABSTRACT:"AT-rich interaction domain 2" OR TITLE:"AT-rich interactive domain-containing protein 2" OR ABSTRACT:"AT-rich interactive domain-containing protein 2" OR TITLE:"KIAA1557" OR ABSTRACT:"KIAA1557" OR TITLE:"DKFZp686G052" OR ABSTRACT:"DKFZp686G052" OR TITLE:"FLJ30619" OR ABSTRACT:"FLJ30619") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARID2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetMAP2K4
Shares Biliary tract cancer (all types), Skin cancer (all types), Oesophageal cancer, Hepatocellular carcinoma.
- TargetFOXP1
Shares Biliary tract cancer (all types), Skin cancer (all types), Oesophageal cancer, CIViC.
- TargetTET1
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Hepatocellular carcinoma, CIViC.
- TargetCDH11
Shares Biliary tract cancer (all types), Skin cancer (all types), Oesophageal cancer, Hepatocellular carcinoma.
- TargetZNF521
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Oesophageal cancer, Hepatocellular carcinoma.
- TargetPBRM1
Shares Biliary tract cancer (all types), Skin cancer (all types), Oesophageal cancer, CIViC.
- TargetFGFR4
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, CIViC, IntOGen.
- TargetBAP1
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, CIViC.